http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100554220-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/H02J7-0047 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/H01R13-639 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/H01R13-717 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-48 |
| filingDate | 2003-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2006-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2006-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-100554220-B1 |
| titleOfInvention | Anticancer substance screening method using enzyme-substrate specificity of RT / PCC and PDX1 |
| abstract | The present invention reveals that phosphoinositide dependent kinas-1 (PDK1), a signaling protein that induces cell proliferation, is a phosphorylation substrate of RET / PTC tyrosine kinase, and measured the activity of RET / PTC in vitro or in vivo using the same. It is to suggest a method for screening, a method for screening the RET / PTFE activity inhibitor and a method for analyzing the performance of the RET / PTFE activity inhibitor.n n n Since the present invention can easily measure RET / PTC activity, select RET / PTC inhibitors, and analyze performance by using enzyme-substrate specificity of RET / PTC protein and PDK1 protein, which are different from the conventional methods. It can be usefully used as a new anticancer substance development system.n n n n Thyroid, Papillary Cancer, RET / PTC, PDK1, Phosphorylation, Tyrosine |
| priorityDate | 2003-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 102.